12.26.14
Columbia, Md. cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopedics and sports medicine, has entered into an exclusive, worldwide partnership with Stryker Corporation for the commercialization and development of Osiris’ viable bone matrix tissue form.
“Osiris was the pioneer in the allograft bone graft market with the introduction of Osteocel in 2005,” said Lode Debrabandere, Ph.D., president and CEO of Osiris. “This partnership combines the strengths of Stryker, an industry leader in marketing orthopaedic and spine products and of Osiris, the cellular regenerative medicine leader who developed this next generation viable bone matrix.”
The agreement provides Kalamazoo, Mich.-based Stryker with exclusive, worldwide rights to Osiris’ viable bone matrix under the name Bio4. Osiris will be responsible for the manufacturing, continued research and product improvement activities while Stryker will be responsible for the commercialization and marketing of Bio4. To demonstrate the differentiating benefits and ensure the continued success and growth of this innovative product, both organizations will collaborate on the design and conduct of future clinical development programs.
Bio4 is a bone allograft that contains both viable cells and growth factors. According to Osiris, it is a safe alternative to autografts that minimizes the potential for harvest site co-morbidities. Bio4 is composed of a structural extracellular matrix, osteogenic and angiogenic growth factors, endogenous mesenchymal stem cells and osteoblasts. It possesses osteoconductive, osteoinductive, osteogenic and angiogenic properties that are required for bone repair and regeneration. It is ready-to-use out of the package. Prior to the agreement with Stryker, the product was branded as OvationOS.
“Osiris was the pioneer in the allograft bone graft market with the introduction of Osteocel in 2005,” said Lode Debrabandere, Ph.D., president and CEO of Osiris. “This partnership combines the strengths of Stryker, an industry leader in marketing orthopaedic and spine products and of Osiris, the cellular regenerative medicine leader who developed this next generation viable bone matrix.”
The agreement provides Kalamazoo, Mich.-based Stryker with exclusive, worldwide rights to Osiris’ viable bone matrix under the name Bio4. Osiris will be responsible for the manufacturing, continued research and product improvement activities while Stryker will be responsible for the commercialization and marketing of Bio4. To demonstrate the differentiating benefits and ensure the continued success and growth of this innovative product, both organizations will collaborate on the design and conduct of future clinical development programs.
Bio4 is a bone allograft that contains both viable cells and growth factors. According to Osiris, it is a safe alternative to autografts that minimizes the potential for harvest site co-morbidities. Bio4 is composed of a structural extracellular matrix, osteogenic and angiogenic growth factors, endogenous mesenchymal stem cells and osteoblasts. It possesses osteoconductive, osteoinductive, osteogenic and angiogenic properties that are required for bone repair and regeneration. It is ready-to-use out of the package. Prior to the agreement with Stryker, the product was branded as OvationOS.